Search Filters

  • Presentation Format
  • Media Type
  • Diagnosis / Condition
  • Diagnosis Method
  • Patient Populations
  • Treatment / Technique

Estimation of Patient Acceptable Symptom State (PASS) and Treatment Failure (TF) Threshold Values for the Achilles Tendon Total Rupture Score (ATRS) at 6 Months, 1 Year and 2 Years After Acute Achilles Tendon Rupture.

Estimation of Patient Acceptable Symptom State (PASS) and Treatment Failure (TF) Threshold Values for the Achilles Tendon Total Rupture Score (ATRS) at 6 Months, 1 Year and 2 Years After Acute Achilles Tendon Rupture.

Allan Cramer, MD, PhD, DENMARK Lina Holm Ingelsrud, PT, MSc, DENMARK Maria Swennergren Hansen, PT, PhD, DENMARK Per Hölmich, DMSc, Prof., DENMARK Kristoffer W. Barfod, MD, PhD, Prof., DENMARK

Sports Orthopedic Research Center - Copenhagen (SORC-C), Departement of Orthopedic Surgery, Hvidovre Hospital., Hvidovre, DENMARK


2021 Congress   ePoster Presentation     rating (1)

 

Anatomic Location

Anatomic Structure

Diagnosis / Condition

Diagnosis Method

Sports Medicine

This media is available to current ISAKOS Members, Global Link All-Access Subscribers and Webinar/Course Registrants only.

Summary: The estimated Patient Acceptable Symptom State (PASS) and Treatment Failure (TF) threshold values can help interpret the outcome of acute Achilles tendon rupture when measured with the Achilles Tendon Total Rupture Score (ATRS).


Objective

Interpretation of the Achilles tendon Rupture Score (ATRS) is challenging because no knowledge exists about at which score the patients consider the outcome of treatment as satisfactory. The aims of this study were 1) to describe the proportion of patients who find their symptom levels to be satisfactory, to reflect treatment failure or neither, and 2) to estimate the Patient Acceptable Symptom State (PASS) and the Treatment Failure (TF) threshold values for ATRS at 6 months, 1 year, and 2 years after ATR.

Methods

The nationwide Danish Achilles tendon Database (DADB) includes patients treated operatively or non-operatively after ATR. 1 May 2020 the included patients were asked at 6 months, 1 year, or 2 years after their ATR whether they considered their symptom level to be satisfactory (PASS anchor question), and if not, if they considered their symptom level to reflect treatment failure (TF anchor question). Patients who on 1 January 2021 had answered both the anchor questions and the ATRS were included in the study population for the given time point. The PASS and TF threshold values of ATRS at each follow-up time point were estimated using the adjusted predictive modeling method, which is based on logistic regression. Confidence Intervals (CI) were derived with non-parametric bootstrapping.

Results

166 (51%) patients were included at 6 months, 248 (50%) patients at 1 year, and 287 (57%) patients at 2 years. The proportion of patients who considered their symptom level to be satisfactory was 61% at 6 months, 50% at 1 year, and 66% at 2 years. The proportion of patients who considered their symptom level to reflect treatment failure was 5% at 6 months, 11% at 1 year, and 10% at 2 years. The ATRS PASS threshold value (95% CI) was 49 (46-52) at 6 months, 57 (54-60) at 1 year, and 52 (49-55) at 2 years. TF threshold value (95% CI) was 30 (23-36) at 6 months, 33 (26-40) at 1 year and 35 (29-39) at 2 years.

Conclusion

The PASS threshold value for ATRS ranged between 49 and 57. The TF threshold values ranged between 30 and 35. The values can help interpret the outcome of ATR when measured with the ATRS. At 6 months to 2 years after ATR, 50-66% of the patients had a satisfactory symptom level, while 5-11% considered their symptom levels to reflect treatment failure.


More ISAKOS 2021: Global Content